Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically-suppressed HIV-1-infected adolescents.

Jantarabenjakul W, Anugulruengkitt S, Kasipong N, Thammajaruk N, Sophonphan J, Bunupuradah T, Cressey TR, Colbers A, Burger DM, Phongsamart W, Puthanakit T, Pancharoen C; HIVNAT 220 study.

Antivir Ther. 2017 Oct 10. doi: 10.3851/IMP3198. [Epub ahead of print]

PMID:
28994660
2.

Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling.

Schalkwijk S, Buaben AO, Freriksen JJM, Colbers AP, Burger DM, Greupink R, Russel FGM.

Clin Pharmacokinet. 2017 Jul 25. doi: 10.1007/s40262-017-0583-8. [Epub ahead of print]

PMID:
28744795
3.

Does a glass of Coke boost the exposure to imatinib in gastrointestinal stromal tumour patients after gastrectomy?

Lubberman FJE, Gelderblom H, Wilmer CM, Kweekel DM, Desar IME, Colbers A, Burger D, van der Graaf WTA, van Erp N.

Br J Clin Pharmacol. 2017 Oct;83(10):2312-2314. doi: 10.1111/bcp.13333. Epub 2017 Jul 4. No abstract available.

PMID:
28677263
4.

Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women.

Schalkwijk S, Colbers A, Konopnicki D, Gingelmaier A, Lambert J, van der Ende M, Moltó J, Burger D; Pharmacokinetics of newly developed antiretroviral agents in HIV-infected pregnant women (PANNA) Network.

Clin Infect Dis. 2017 Oct 15;65(8):1335-1341. doi: 10.1093/cid/cix534.

PMID:
28595298
5.

Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers.

Smolders EJ, Colbers A, de Kanter CTMM, Velthoven-Graafland K, Wolberink LT, van Ewijk-Beneken Kolmer N, Drenth JPH, Aarnoutse RE, Tack CJ, Burger DM.

Br J Clin Pharmacol. 2017 Oct;83(10):2225-2234. doi: 10.1111/bcp.13323. Epub 2017 Jun 6.

PMID:
28474741
6.

Brief Report: Pharmacokinetics of Crushed Elvitegravir Combination Tablet Given With or Without Enteral Nutrition.

Jongbloed-de Hoon M, Colbers A, Velthoven-Graafland K, Duisenberg-van Essenberg M, Kruijssen M, Abbink E, van Crevel R, Burger D.

J Acquir Immune Defic Syndr. 2017 Apr 15;74(5):571-574. doi: 10.1097/QAI.0000000000001296.

PMID:
28166190
7.

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.

Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M; PanACEA consortium.

Lancet Infect Dis. 2017 Jan;17(1):39-49. doi: 10.1016/S1473-3099(16)30274-2. Epub 2016 Oct 26.

8.

Dolutegravir in breast milk and maternal and infant plasma during breastfeeding.

Kobbe R, Schalkwijk S, Dunay G, Eberhard JM, Schulze-Sturm U, Hollwitz B, Degen O, Teulen M, Colbers A, Burger D.

AIDS. 2016 Nov 13;30(17):2731-2733. No abstract available.

PMID:
27782968
9.

Etravirine Pharmacokinetics in HIV-Infected Pregnant Women.

Mulligan N, Schalkwijk S, Best BM, Colbers A, Wang J, Capparelli EV, Moltó J, Stek AM, Taylor G, Smith E, Hidalgo Tenorio C, Chakhtoura N, van Kasteren M, Fletcher CV, Mirochnick M, Burger D.

Front Pharmacol. 2016 Aug 4;7:239. doi: 10.3389/fphar.2016.00239. eCollection 2016.

10.

CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.

Zhu L, Brüggemann RJ, Uy J, Colbers A, Hruska MW, Chung E, Sims K, Vakkalagadda B, Xu X, van Schaik RH, Burger DM, Bertz RJ.

J Clin Pharmacol. 2017 Feb;57(2):235-246. doi: 10.1002/jcph.798. Epub 2016 Aug 23.

PMID:
27432796
11.

Substantially lowered dolutegravir exposure in a treatment-experienced perinatally HIV-1-infected pregnant woman.

Schalkwijk S, Feiterna-Sperling C, Weizsäcker K, Colbers A, Bührer C, Greupink R, Russel FG, Burger D; PANNA network.

AIDS. 2016 Jul 31;30(12):1999-2001. doi: 10.1097/QAD.0000000000001123. No abstract available.

PMID:
27428578
12.

A new paediatric formulation of valaciclovir: development and bioequivalence assessment.

Bastiaans DE, Bartels-Wilmer CM, Colbers AP, Heijens CA, Velthoven-Graafland K, Smeets OS, Vink N, Harbers VE, Warris A, Burger DM.

Arch Dis Child. 2016 Oct;101(10):971-2. doi: 10.1136/archdischild-2015-310266. Epub 2016 May 9. No abstract available.

PMID:
27162003
13.

First reported use of elvitegravir and cobicistat during pregnancy.

Schalkwijk S, Colbers A, Konopnicki D, Greupink R, Russel FG, Burger D; PANNA network.

AIDS. 2016 Mar 13;30(5):807-8. doi: 10.1097/QAD.0000000000000976. No abstract available.

PMID:
26913711
14.

The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women.

Schalkwijk S, Colbers A, Konopnicki D, Weizsäcker K, Moltó J, Tenorio CH, Hawkins D, Taylor G, Wood C, van der Ende M, Burger D; PANNA network.

AIDS. 2016 May 15;30(8):1239-44. doi: 10.1097/QAD.0000000000001046.

PMID:
26836789
15.

Placental transfer of the HIV integrase inhibitor dolutegravir in an ex vivo human cotyledon perfusion model.

Schalkwijk S, Greupink R, Colbers AP, Wouterse AC, Verweij VG, van Drongelen J, Teulen M, van den Oetelaar D, Burger DM, Russel FG.

J Antimicrob Chemother. 2016 Feb;71(2):480-3. doi: 10.1093/jac/dkv358. Epub 2015 Nov 3.

PMID:
26538508
16.

Pharmacokinetic drug-drug interaction study between raltegravir and citalopram.

Blonk MI, Langemeijer CC, Colbers AP, Hoogtanders KE, van Schaik RH, Schouwenberg BJ, Burger DM.

Antivir Ther. 2016;21(2):143-52. doi: 10.3851/IMP2993. Epub 2015 Sep 16.

PMID:
26375942
17.

Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.

Colbers A, Greupink R, Litjens C, Burger D, Russel FG.

Clin Pharmacokinet. 2016 Mar;55(3):381-96. doi: 10.1007/s40262-015-0325-8.

18.

Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women.

Colbers A, Best B, Schalkwijk S, Wang J, Stek A, Hidalgo Tenorio C, Hawkins D, Taylor G, Kreitchmann R, Burchett S, Haberl A, Kabeya K, van Kasteren M, Smith E, Capparelli E, Burger D, Mirochnick M; PANNA Network and the IMPAACT 1026 Study Team.

Clin Infect Dis. 2015 Nov 15;61(10):1582-9. doi: 10.1093/cid/civ587. Epub 2015 Jul 22.

19.

The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity.

Welzen ME, Dezentjé VO, van Schaik RH, Colbers AP, Guchelaar HJ, van Erp NP, den Hartigh J, Burger DM, van Laarhoven HW.

Ther Drug Monit. 2015 Aug;37(4):501-7. doi: 10.1097/FTD.0000000000000195.

PMID:
26192892
20.

Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients.

Lempers VJ, Schouten JA, Hunfeld NG, Colbers A, van Leeuwen HJ, Burger DM, Verweij PE, Pickkers P, Brüggemann RJ.

Antimicrob Agents Chemother. 2015 Aug;59(8):4403-9. doi: 10.1128/AAC.00623-15. Epub 2015 May 11.

Supplemental Content

Loading ...
Support Center